Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP).
Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H. Shiraki M, et al. Among authors: ohta h. J Bone Miner Metab. 2011 Jan;29(1):37-43. doi: 10.1007/s00774-010-0188-x. Epub 2010 May 13. J Bone Miner Metab. 2011. PMID: 20461422 Clinical Trial.
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03.
Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M. Tanaka S, et al. Among authors: ohta h. J Bone Miner Metab. 2017 Jul;35(4):385-395. doi: 10.1007/s00774-016-0768-5. Epub 2016 Aug 2. J Bone Miner Metab. 2017. PMID: 27484436 Clinical Trial.
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) research group. Uemura Y, et al. Among authors: ohta h. J Bone Miner Metab. 2019 May;37(3):491-495. doi: 10.1007/s00774-018-0942-z. Epub 2018 Jul 17. J Bone Miner Metab. 2019. PMID: 30019249
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.
Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M; Adequate Treatment of Osteoporosis (A-TOP) research group. Taguchi A, et al. Among authors: ohta h. J Bone Miner Metab. 2019 Sep;37(5):886-892. doi: 10.1007/s00774-019-00990-5. Epub 2019 Feb 4. J Bone Miner Metab. 2019. PMID: 30719580 Clinical Trial.
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y; Risedronate Phase III Research Group. Kishimoto H, et al. Among authors: ohta h. J Bone Miner Metab. 2006;24(5):405-13. doi: 10.1007/s00774-006-0706-z. J Bone Miner Metab. 2006. PMID: 16937274 Clinical Trial.
[A-TOP research group/JOINT-02].
Kuroda T, Ohta H, Shiraki M, Miyakawa N, Hosoi T, Nakamura T, Fukunaga M, Orimo H. Kuroda T, et al. Among authors: ohta h. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:271-4. Nihon Rinsho. 2007. PMID: 18161118 Review. Japanese. No abstract available.
2,448 results